Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Accumulated Expenses data on file, last reported at $17.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 407.77% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 407.77% YoY) and the FY2025 annual result came in at $19.0 million, down 5.0% from the prior year.
• Other Accumulated Expenses fell to $17.0 million in Q1 2026 per RARE's latest filing, from $19.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $59.9 million in Q3 2022 and bottomed at $3.3 million in Q1 2025.
• The 5-year median for Other Accumulated Expenses is $36.8 million (2022), against an average of $34.0 million.
• The widest annual swing landed in 2025, when Other Accumulated Expenses plunged 93.33%; it then jumped 407.77% in 2026.
• Tracing RARE's Other Accumulated Expenses over 5 years: stood at $52.2 million in 2022, then decreased by 2.64% to $50.8 million in 2023, then slumped by 60.63% to $20.0 million in 2024, then slipped by 5.0% to $19.0 million in 2025, then fell by 10.53% to $17.0 million in 2026.
• Per Business Quant, the three latest RARE Other Accumulated Expenses figures stand at $17.0 million (Q1 2026), $19.0 million (Q4 2025), and $19.0 million (Q3 2025).

Peer Comparison